Market cap
$71.6m
End-of-day close multiplied by current shares on issue.
Earnings returned to growth on a -1.9% revenue base, but FCF of NZ$6.1m reflects capex falling 92% and an unusual working capital release.
Revenue context before the current result.
EBITDA margin across covered periods.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Market context
A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.
The latest close and share count context for the market price.
Market cap
$71.6m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
10.69x
Recent market cap compared with trailing earnings.
EPS
0.03
Recent filing-derived earnings per share.
PEG
2.28x
P/E compared with recent earnings growth.
EV/EBITDA
4.48x
Enterprise value compared with recent EBITDA.
P/FCF
8.43x
Market cap compared with recent free cash flow.
P/B
0.99x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
6.7%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
HY25 vs HY24
Revenue
$82.2m
-1.9% ↓ vs $83.8m
EBITDA
$7.8m
+5.4% ↑ vs $7.4m
Net profit after tax
$3m
+20.0% ↑ vs $2.5m
Net cash inflow from operating activities
$6.3m
+27.0% ↑ vs $4.9m
Interim dividend per share
0.7c
— vs —
Profit before tax
$4.1m
+17.1% ↑ vs $3.5m
Cash and cash equivalents
$1.8m
n/m ↑ vs $0.15m
Total assets
$105.5m
-2.0% ↓ vs $107.6m
What changed
That swing, combined with capex falling 92.1% to NZ$0.2m from NZ$2.5m, is the dominant reason pre-lease free cash flow stepped up to NZ$6.1m versus a 3-period mean of NZ$2.7m.
Underlying earnings did return to growth from a depressed base. Revenue fell -1.9% to NZ$82.2m, but EBITDA rose 5.4% to NZ$7.8m, PBT grew 17.1% to NZ$4.1m and NPAT grew 20.0% to NZ$3.0m. Operating cash flow rose 27% to NZ$6.3m, net debt fell to NZ$9.7m (1.2x EBITDA, from 1.9x), and the company declared a 0.65cps interim dividend implying a 65.0% payout against current-period NPAT.
What matters
OCF/EBITDA conversion of 80.3% sits at the upper edge of the historical 47.7%–80.6% range, which is genuinely strong. However, both the working-capital release (classified below normal range) and the near-elimination of capex contributed materially. Inventory days fell to 0.7 from 4.2 prior, and inventories declined NZ$1.6m on the balance sheet — investors should expect some of that to reverse in normal trading.
Profit growth is from a low base. The 17.1% PBT and 20.0% NPAT growth rates are above-normal-range only because the prior 3-period mean was -35.2% and -32.8% respectively. PBT margin of 5.0% and EBITDA margin of 9.5% remain within the historical 4.2%–8.7% and 8.4%–12.2% ranges and slightly below the 3-period means, so this is recovery off a depressed prior comparable rather than expansion above trend.
Leverage improved without a tax distortion. Net debt fell NZ$4.4m year-on-year and the effective tax rate of 28.1% is essentially flat versus 28.3%, so the earnings improvement is not a tax-line artefact. Equity rose NZ$5.8m and total liabilities fell NZ$7.9m, leaving the balance sheet measurably stronger.
Expectations
Annualising the half implies a NZ$164.4m run-rate against last year's NZ$175.7m full-year revenue, which would extend the multi-year revenue decline, though the historical pattern shows revenue growth of -1.9% sits within the recent normal range.
The dividend at 65.0% of half-year NPAT is supportable given the FCF print, but durability hinges on whether capex stays near zero — that intensity ratio of 0.2% of revenue is well below FY24 levels and is unlikely to be a steady-state assumption.
Quality of result
Gross margin reference of 47.9% in the prior comparable suggests the cost base was already being managed; the EBITDA dollar gain of NZ$0.4m on lower revenue indicates some genuine cost leverage.
The cash story is more timing-sensitive. Pre-lease FCF of NZ$6.1m converts at 205.4% of NPAT, which is mechanically unsustainable. The drivers were (1) a working-capital release of NZ$1.6m versus a typical build, including inventory falling 83.4%, and (2) capex of NZ$0.2m versus NZ$2.5m prior — a 92.1% reduction. Net debt reduction of NZ$2.1m since March is real, but a normalised capex year combined with any working-capital reversal would compress FCF materially closer to the historical NZ$2.4m–NZ$3.1m range.
Unresolved
This briefing cannot assess customer cohort behaviour, competitive positioning, or any forward outlook because no segment data, active-customer disclosures or guidance were supplied.
Chat
Ask follow-up questions about My Food Bag Group's HY25 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load analytical metrics.
Open to load key metrics.
company filing
HY25 / results announcementInterim Report
HY25 / financial reportInterim Results Presentation
HY25 / results presentationcompany filing
HY24 / results announcementInterim Report
HY24 / financial reportMedia Release
HY24 / media releasecompany filing
FY24 / results announcementInterim Report
FY24 / financial reportMedia Release
FY24 / media releaseResults of 2023 Annual Meeting
HY25 / commentaryRelated insights
Cross-company views selected from the metrics in this briefing.
Cash conversion quality
This result converted 80.3% of EBITDA to operating cash flow, +13.7pp versus the prior comparable period.
Dividend coverage and payout pressure
Dividend payout versus NPAT is 65.0%.
Leverage and balance-sheet risk
Net debt / EBITDA is 1.20x, -0.70x versus the prior comparable period.
Earnings quality and statutory distortions
PBT and NPAT growth diverged by 2.9pp.
Get the next My Food Bag Group briefing and related NZX reporting-season updates by email.